Case Reports in Pathology

Case Reports in Pathology / 2021 / Article

Case Report | Open Access

Volume 2021 |Article ID 8819560 | https://doi.org/10.1155/2021/8819560

Yutaka Tsutsumi, Kentaro Odani, Yasuhito Kaneko, Hideo Hashizume, Mitsuhiro Tachibana, "Cutaneous Coinfection of Cytomegalovirus and Mycobacterium chelonae Accelerated by Immunosuppression", Case Reports in Pathology, vol. 2021, Article ID 8819560, 10 pages, 2021. https://doi.org/10.1155/2021/8819560

Cutaneous Coinfection of Cytomegalovirus and Mycobacterium chelonae Accelerated by Immunosuppression

Academic Editor: Denise Tostes Oliveira
Received21 May 2020
Revised08 Jan 2021
Accepted22 Jan 2021
Published30 Jan 2021

Abstract

A mildly diabetic 58-year-old male had traumatic ulceration on the left popliteal fossa, and the lesion progressed to a painful 6 cm deep ulcer. After surgical debridement and skin grafting, ulceration recurred. Pyoderma gangrenosum was clinically diagnosed after the first biopsy, indicating a noninfective ulcer. Immunosuppressive therapy (prednisolone and cyclosporine A) induced complete epithelialization in three months. Four months later, subcutaneous nonulcerated nodules appeared on the anterior area of the left lower leg. Subcutaneous induration progressed and ulceration recurred, so that immunosuppressive therapy continued for one year. Cytomegalovirus (CMV) viremia was detected, and the second biopsy demonstrated CMV inclusions of endothelial and perivascular cells in fibrosing septolobular panniculitis. Cyclosporine A was cancelled, prednisolone was tapered, and ganciclovir started. Viremia soon disappeared, but the lesion progressed to large induration with multiple ulcers measuring up to 3 cm. The third biopsy disclosed infection of Gram-positive mycobacteria, accompanying fat droplet-centered suppurative granulomas without CMV infection. Microbial culture identified Mycobacterium chelonae. Clarithromycin with thermotherapy was effective. A review of the second biopsy confirmed coinfection of CMV and Gram-positive mycobacteria. Immunostaining using a panel of anti-bacterial antibodies visualized the mycobacteria in the lesion. Positive findings were obtained with antibodies to Bacillus Calmette-Guérin, Bacillus cereus, MPT64 (Mycobacterium tuberculosis-specific 24 kDa secretory antigen), LAM (Mycobacterium tuberculosis-related lipoarabinomannan), and PAB (Propionibacterium acnes-specific lipoteichoic acid).

1. Introduction

Immunosuppressive conditions may provoke opportunistic skin infection of a variety of bacteria, fungi, and viruses [1, 2]. The present article describes a case of pyoderma gangrenosum on the left popliteal fossa, followed by immunosuppressive therapy-induced opportunistic dual skin infection of cytomegalovirus (CMV) and Mycobacterium chelonae on the left lower leg. Histopathological and immunohistochemical features of this rare combination of pathogens are detailed.

2. Case Report

A 58-year-old Japanese man slipped and fell on the road to have his left knee contused, resulting in a 1.5 cm sized shallow ulceration. The patient had suffered from hypertension and mild type 2 diabetes mellitus for two years, but no history of autoimmune disorders. Serum antibodies against insulin and glutamic acid decarboxylase were negative, excluding the possibility of type 1 diabetes mellitus. He had smoked 15 cigarettes per day for more than 40 years. Five months later, a painful skin ulcer, 6 cm in size, occurred on the inner side of the left popliteal fossa (at the same site of contusion). No pathogens were identified in the biopsy specimen, and microbial culture was negative. Surgical debridement and full-thickness grafting from the abdominal skin were performed by a plastic surgeon, but half of the skin flap was eventually impaired, leaving a 3 cm sized deep ulcer with severe pain. The patient was then consulted to dermatologists. Clinical findings, as well as the first biopsy features displaying nonspecific and noninfective ulcer, were consistent with pyoderma gangrenosum (Figure 1). The serum level of granulocyte colony-stimulating factor, a biomarker of pyoderma gangrenosum [3], was elevated to 48.1 pg/mL (reference  pg/mL). Administration of prednisolone (PSL) (20 mg/day) and cyclosporine A (CyA: 100 mg/day) started. In order to control exacerbation of the skin lesion, medication of PSL plus CyA was maintained, while PSL was gradually tapered to 10 mg/day. Complete epithelialization was achieved three months later.

Four months later, subcutaneous nonulcerated, painful nodules appeared on the anterior area of the left lower leg, 20 cm distal from the primary ulcer caused by pyoderma gangrenosum. Ulceration recurred, and subcutaneous induration soon progressed toward both the distal and proximal directions. Immunosuppressive therapy restarted, but the painful ulcer persisted for one year. At this point of time, CMV viremia was identified, and the second skin biopsy from one of the subcutaneous nodules identified CMV inclusions in the subcutaneous tissue with fibrosing septolobular panniculitis. The CMV antigens were immunohistochemically visualized in the viral inclusions with 1 : 200 diluted cocktail monoclonal antibodies, CCH2+DDG9, available from Agilent Technologies (Figure 2). Both endothelial cells and perivascular stromal cells were infected. The dermis was free of inflammation. CyA was cancelled, PSL was reduced to 5 mg/day, and instead, ganciclovir (900 mg/day) was administered. Viremia soon disappeared, but the lower leg lesion progressed to form multiple ulcers. The third skin biopsy disclosed that infection involved both the dermis and the subcutaneous fat tissue. Suppurative granulomas (small abscesses surrounded by epithelioid granulomas) were dispersed (Figure 3). Gram-positive acid-fast bacilli were identified in microabscesses and also in fat droplets surrounded by suppurative granulomas (Figure 4). Caseous necrosis was focally associated. Grocott stain gave negative results. CMV infection was no longer identified. The second skin biopsy was retrospectively reevaluated, and Gram-positive acid-fast bacilli were identified mainly in microabscesses and in fat droplets surrounded by suppurative granulomas, multifocally distributed in the inflamed subcutaneous tissue. The final diagnosis of the second biopsy was thus subcutaneous coinfection of CMV and nontuberculous mycobacteria.

Microbial culture on 2% Ogawa medium at 37°C identified rapidly growing nontuberculous mycobacteria. The bacteria were acid-fast and Gram-positive. Mycobacterium chelonae was identified by analyzing with Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) by using the MALDI Biotyper (Bruker Japan Daltonics division, Yokohama) (Figure 5) [4]. The log score value for M. chelonae was more than 2.0 (2.208).

Clarithromycin administration (800 mg/day), combined with thermotherapy using disposal pocket body warmers for one hour twice a day, resulted in marked regression of the ulcers. PSL tapering induced subcutaneous nodularity with ulceration, and thus, clarithromycin treatment was kept to date. After chemotherapy for 15 months, epithelialization was almost achieved. Valganciclovir was administered when CMV viremia reappeared.

Metformin (an oral antidiabetic) and sitagliptin phosphate hydrate (a selective inhibitor of dipeptidyl peptidase-4) continued for controlling type 2 diabetes mellitus. Mitiglinide calcium hydrate (a stimulator of insulin secretion) was added after the appearance of the skin ulceration for one year. During the clinical course, the patient’s blood glucose levels were persistently hyperglycemic, ranging from 106 to 186 mg/dL but without glycosuria. Mild proteinuria ranging from 15 to 100 mg/dL was noted, indicating the complication of stage 2 (early) diabetic nephropathy. His HbA1c levels ranged from 6.4 to 7.3% (standard levels: 4.1–6.2%). The patient thus suffered from mild and controlled diabetes mellitus.

For characterizing the mycobacteria colonizing the skin lesion in the second and third skin biopsy specimens, immunostaining using selected antibodies was performed, as indicated in Table 1. An amino acid polymer method (Simple Stain Max-PO, Nichirei Biosciences, Tokyo) was employed. As reported in the previous article describing a low-specificity and high-sensitivity immunostaining with widely cross-reactive antibacterial antisera [5], the mycobacteria were visualized in formalin-fixed, paraffin-embedded sections. The antibodies gave clearly positive signals in the cytoplasm of macrophages infiltrating in the lesion, in addition to long rods labeled with Gram and Ziehl-Neelsen stains. Figure 6 illustrates positive findings with rabbit antisera to Bacillus Calmette-Guérin (BCG) [6], Bacillus cereus [5], MPT64 (also called as protein Rv1980c, M. tuberculosis-specific 24 kDa secretory antigen) [7], and monoclonal antibodies to LAM (M. tuberculosis-related lipoarabinomannan) [8] and PAB (Propionibacterium acnes-specific lipoteichoic acid) [9]. Antiserum to Treponema pallidum gave weak immunoreactivity. Escherichia coli antigens were scarcely observed. The background staining was minimal.


Target antigenAnimal/cloneDilutionAntigen retrievalSource

Bacillus Calmette-Guérin (BCG)Rabbit antiserum1 : 10,000NoneAgilent
MPT64 (RV1980C, 24 kDa protein)Rabbit antiserum1 : 800HIER in 10 mM CB (pH 6)Abcam
LAM (lipoarabinomannan)Mouse TMDU31 : 1,000HIER in 10 mM CB (pH 6)MBL
PAB (Propionibacterium acnes-specific lipoteichoic acid)Mouse TMDU21 : 4,000HIER in 10 mM CB (pH 6)MBL
Bacillus cereusRabbit antiserum1 : 500HIER in 10 mM CB (pH 6)Abcam
Treponema pallidumRabbit antiserum1 : 1,000HIER in 1 mM EDTA (pH 8)BM
Escherichia coliRabbit antiserum1 : 20,000Proteinase K digestionAgilent

MPT: mycobacterial protein tuberculosis; HIER: heat-induced epitope retrieval; CB: citrate buffer; EDTA: ethylenediamine tetraacetic acid; Agilent: Agilent Technologies (Santa Clara, CA, USA); MBL: Medical and Biological Laboratories (Nagoya, Japan); Abcam: Abcam plc (Cambridge, UK); BM: Biocare Medical LLC (Pacheco, Philippines).

3. Discussion

Opportunistic infection caused by a variety of bacteria, fungi, or viruses occurs in the skin under the immunosuppressive state such as acquired immunodeficiency syndrome (AIDS) and after the use of immunosuppressive agents [1, 2]. One of the authors (YT) described histopathological features of such conditions in a textbook entitled Pathology of Skin Infections published in 2013 [10]. We describe herein a case of cutaneous coinfection of CMV and M. chelonae, provoked by immunosuppressive therapy against pyoderma gangrenosum. The patient suffered from mild and controlled type 2 diabetes mellitus. Pyoderma gangrenosum is characterized by noninfectious autoimmune-type progressive skin ulceration [11], successfully treated with immunosuppressive agents [12].

Opportunistic skin infection of CMV is rare. CMV mainly affects vascular endothelial cells and perivascular stromal cells, and multifocal anogenital ulcerations are most frequently encountered in AIDS patients [13]. Cutaneous lesions with verrucous elevations [14] and septal panniculitis [15] have also been described in non-AIDS immunosuppressed patients. Since the skin ulcer remained unchanged after ganciclovir treatment, Grushchak et al. regarded CMV infection as a bystander phenomenon [16]. The skin lesion in the present case demonstrated features of septolobular panniculitis with CMV inclusions in endothelial and perivascular stromal cells, but the lesion progressed to form large induration with multiple ulcers after gancyclovir treatment. It is reasonable to consider the CMV infection as bystander incidence associated with nontuberculous mycobacteriosis. In other words, when CMV inclusions are noted in nodular or ulcerated skin lesions, primary causative microbes other than CMV should be searched under the microscope, as was so in the present case.

Varied nontuberculous mycobacteria affect the skin, including M. avium-intracellulare complex, M. marinum, M. ulcerans, M. fortuitum, and M. chelonae-abscessus complex [17, 18]. Reportedly, rapidly growing mycobacteria (RGM) form colonies on a common chocolate agar medium when the culture period is prolonged to two weeks or more [19].

M. chelonae was first isolated from the tortoise by Friedmann in 1902 [20]. M. chelonae belongs to nonchromogenic RGM (Runyon group IV), widely distributed in environmental water [21]. This zoonotic mycobacterium, categorized in M. chelonae-abscessus complex, causes opportunistic infection in the human skin, as well as infection in aquatic animals such as the reptiles and fish [22]. Of notice is that not only traumatic injuries but also surgical procedures make risk factors of human infection [23]. It is plausible that in the present case, medical disposals caused iatrogenic infection of the environmental pathogen. Immunosuppression and diabetic conditions accelerated opportunistic infection, as reported previously [17, 18, 22]. Microscopically, infection of RGM, including M. chelonae, provokes abscess-forming granulomas (suppurative granulomas): some lesions are recognized as abscess surrounded by abortive granuloma formation, while the others predominantly reveal epithelioid granulomas [24, 25]. Acid-fast bacilli are characteristically identified in the lipid droplets (vacuoles) often located in the center of suppurative granulomas. It is noteworthy that the bacilli are positively labeled with Gram stain: namely, Gram positivity is a feature of RGM [26].

The cell wall of mycobacteria contains voluminous mycolic acids, extremely long fatty acids, as molecular forms of mycolic acid-containing glycolipid such as trehalose dimycolate and trehalose monomycolate, giving lipophilic nature of mycobacteria [27]. RGM are characterized by the presence of an additional mycolate, glucose mycolate, on the cell wall [28]. Such biological features may be related to the lipid droplet-centered pattern of infection by RGM.

Lipid droplet-centered suppurative granulomas are commonly observed in granulomatous mastitis caused by a lipophilic bacterium, Corynebacterium kroppenstedtii [29]. The Gram-positive rods are uniquely clustered in the lipid droplets surrounded by suppurative granulomas. The histological features are quite similar to those of RGM infection. Unlike other corynebacteria, C. kroppenstedtii lacks mycolic acid but instead contains tuberculostearic acid in the cell wall [30]. It is understandable from both the microscopic appearance and the pharmacodynamic properties of antibiotics [31] that administration of lipophilic antibiotics is essential for treating not only granulomatous mastitis but also RGM infection. The treatment regimen for tuberculosis using hydrophilic antibiotics such as isoniazid, ethambuthol, pyrazinamide, and streptomycin is consistently ineffective for infection of RGM, which are usually resistant to lipophilic rifampicin [18]. In the present case, clarithromycin, a type of lipophilic macrolides, was effective, as has been reported so far [32, 33]. Thermotherapy was also useful [34], based on the biological features of the bacteria showing low optimal temperature (25–37°C) for growth [17, 18].

Immunohistochemical cross-reactivity of rabbit antisera against BCG and B. cereus was observed in the infected lesion. T. pallidum antiserum also showed weak cross-reactivity. Positive signals with low background staining were observed not only on the mycobacteria in the lipid droplets but also in the cytoplasm of macrophages, so that the detection sensitivity was very high [5]. Similar results were observed in granulomatous mastitis [29]. The visualization of microbes within the lesion is essentially important for making a histopathological diagnosis of infection [5]. Another important point of our findings includes the cross-reactivity of antibodies against MPT64, LAM, and PAB to M. chelonae. It has been reported that MPT64 and LAM are specific to M. tuberculosis, and PAB is solely expressed on Propionibacterium (Cutibacterium) acnes [79]. The P. acnes antigens were detected in granulomas of sarcoidosis [35]. The lipophilic bacteria in granulomatous mastitis also expressed LAM and PAB (Tsutsumi, unpublished observation). Such unexpected cross-reactivity should be cautious about applying the antibacterial antibodies as immunohistochemical probes, as has been described previously [5].

4. Conclusion

We reported here rare opportunistic skin coinfection of CMV and M. chelonae, a rapidly growing nontuberculous mycobacterium, after immunosuppressive therapy against pyoderma gangrenosum. It is of note that M. chelonae provoked suppurative granulomas with lipid droplet-centered colonization of Gram-positive and acid-fast rods. Unique immunohistochemical reactivities with a variety of antibacterial antibodies were applicable to visualizing the causative mycobacteria in the lesion.

The patient gave written informed consent to publication of the case report.

Disclosure

The present address of Kentaro Odani is the Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto. The present address of Hideo Hashizume is the Department of Dermatology, Iwata City Hospital, Iwata, Shizuoka.

Conflicts of Interest

The authors do not have any conflict of interest in the present report.

Authors’ Contributions

We declare that all the authors (1) made a substantial contribution to the concept of the case report or interpretation of data and (2) approved the version to be submitted. (3) Each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

Acknowledgments

The authors deeply thank Mr. Izumi Kurita, M.T., Clinical Laboratory Medicine, Shimada Municipal Hospital, Shimada, for identifying M. chelonae.

References

  1. J. W. Tappero, B. A. Perkins, J. D. Wenger, and T. G. Berger, “Cutaneous manifestations of opportunistic infections in patients infected with human immunodeficiency virus,” Clinical Microbiology Reviews, vol. 8, no. 3, pp. 440–450, 1995. View at: Publisher Site | Google Scholar
  2. T. Cunliffe, Opportunistic skin infections, 2015, http://www.pcds.org.uk/clinical-guidance/mycoses-uncommon-types.
  3. K. Kozono, T. Nakahara, S. Kikuchi, E. Itoh, M. Kido-Nakahara, and M. Furue, “Pyoderma gangrenosum with increased levels of serum cytokines,” Journal of Dermatology, vol. 42, no. 12, pp. 1186–1188, 2015. View at: Publisher Site | Google Scholar
  4. M. Neuschlova, M. Vladarova, J. Kompanikova, V. Sadlonova, and E. Novakova, “Identification of Mycobacterium species by MALDI-TOF mass spectrometry,” in Pulmonary Care and Clinical Medicine, M. Pokorski, Ed., vol. 1021 of Advances in Experimental Medicine and Biology, pp. 37–42, Springer, Champions, 2017. View at: Publisher Site | Google Scholar
  5. Y. Tsutsumi, “Low-Specificity and High-Sensitivity Immunostaining for Demonstrating Pathogens in Formalin-Fixed, Paraffin-Embedded Sections,” in Immunohistochemistry - The Ageless Biotechnology, p. 46, IntechOpen, London, UK, 2020. View at: Publisher Site | Google Scholar
  6. K. Kawai and Y. Tsutsumi, “Immunoperoxidase visualization of acid-fast bacilli. A comparison with conventional acid-fast staining,” Byori-to-Rinsho, vol. 2, pp. 862–867, 1984, (in Japanese). View at: Google Scholar
  7. V. P. Myneedu, J. Arora, G. Kumar, A. K. Verma, M. Bhalla, and R. Sarin, “Utility of MPT64 antigen detection for rapid confirmation of Mycobacterium tuberculosis complex,” Journal of Global Infectious Diseases, vol. 7, no. 2, pp. 66–69, 2015. View at: Publisher Site | Google Scholar
  8. Y. Sakakibara, Y. Suzuki, T. Fujie et al., “Radiopathological features and identification of mycobacterial infections in granulomatous nodules resected from the lung,” Respiration, vol. 93, no. 4, pp. 264–270, 2017. View at: Publisher Site | Google Scholar
  9. M. Negi, T. Takemura, J. Guzman et al., “Localization of Propionibacterium acnes in granulomas supports a possible etiologic link between sarcoidosis and the bacterium,” Modern Pathology, vol. 25, no. 9, pp. 1284–1297, 2012. View at: Publisher Site | Google Scholar
  10. Y. Tsutsumi, Pathology of Skin Infections, Nova Biomedical, NY, USA, 2013, https://pathos223.com/bookintroduction/pathology_of_skin_infectious.html.
  11. E. Ruocco, S. Sangiuliano, A. G. Gravina, A. Miranda, and G. Nicoletti, “Pyoderma gangrenosum: an updated review,” Journal of the European Academy of Dermatology and Venereology, vol. 23, no. 9, pp. 1008–1017, 2009. View at: Publisher Site | Google Scholar
  12. A. C. R. Partridge, J. W. Bai, C. F. Rosen, S. R. Walsh, W. P. Gulliver, and P. Fleming, “Effectiveness of systemic treatments for pyoderma gangrenosum: a systematic review of observational studies and clinical trials,” British Journal of Dermatology, vol. 179, pp. 290–295, 2018. View at: Publisher Site | Google Scholar
  13. Y. L. Choi, J. A. Kim, K. T. Jang et al., “Characteristics of cutaneous cytomegalovirus infection in non-acquired immune deficiency syndrome, immunocompromised patients,” British Journal of Dermatology, vol. 155, no. 5, pp. 977–982, 2006. View at: Publisher Site | Google Scholar
  14. K. Mishra, A. Jandial, A. Bal et al., “Verrucous skin lesions in a case of acute lymphoblastic leukemia: a rare manifestation of cytomegalovirus infection,” Indian Journal of Hematology and Blood Transfusion, vol. 34, no. 2, pp. 378–380, 2018. View at: Publisher Site | Google Scholar
  15. M. Ballestero-Díez, S. B. Alvarez-Ruiz, M. Aragüés Montanés, and J. Fraga, “Septal panniculitis associated with cytomegalovirus infection,” Histopathology, vol. 46, no. 6, pp. 720–722, 2005. View at: Publisher Site | Google Scholar
  16. S. Grushchak, K. A. Hutchens, C. Joy, A. Peterson, J. Speiser, and K. Mudaliar, “Cutaneous cytomegalovirus infection in an immunocompetent patient: innocent bystander or culprit?” American Journal of Dermatopathology, vol. 40, no. 4, pp. 295–298, 2018. View at: Publisher Site | Google Scholar
  17. P. Kullavanijaya, “Atypical mycobacterial cutaneous infection,” Clinics in Dermatology, vol. 17, no. 2, pp. 153–158, 1999, discussion 105–106. View at: Publisher Site | Google Scholar
  18. B. A. Forbes, G. S. Hall, M. B. Miller et al., “Practical Guidance for clinical microbiology laboratories: Mycobacteria,” Clinical Microbiological Reviews, vol. 31, no. 2, article e00038, 2018. View at: Publisher Site | Google Scholar
  19. H. Hori, H. Kokashiwa, M. Nishina, Y. Tawada, M. Aono, and T. Nagano, “A case of M. chelonae infection detected by prolonged culture,” Modern Media, vol. 52, pp. 131–134, 2006, (in Japanese). View at: Google Scholar
  20. F. F. Friedmann, “Spontane Lungentuberkulose bei Schildkröten und die Stellung des Tuberkelbazillus im system,” Zeitschrift für Tuberkulose, vol. 4, pp. 439–451, 1903, (in German). View at: Google Scholar
  21. M. A. De Groote and G. Huitt, “Infections due to rapidly growing Mycobacteria,” Clinical Infectious Diseases, vol. 42, no. 12, pp. 1756–1763, 2006. View at: Publisher Site | Google Scholar
  22. S. B. Fogelson, A. C. Camus, W. W. Lorenz et al., “Variation among human, veterinary and environmental Mycobacterium chelonae-abscessus complex isolates observed using core genome phylogenomic analysis, targeted gene comparison, and anti-microbial susceptibility patterns,” PLoS One, vol. 14, no. 3, article e0214274, 2019. View at: Publisher Site | Google Scholar
  23. L. R. Cusumano, V. Tran, A. Tlamsa et al., “Rapidly growing Mycobacterium infections after cosmetic surgery in medical tourists: the Bronx experience and a review of the literature,” International Journal of Infectious Diseases, vol. 63, pp. 1–6, 2017. View at: Publisher Site | Google Scholar
  24. A. D. Gable, D. K. Marsee, D. A. Milner, and S. R. Granter, “Suppurative inflammation with microabscess and pseudocyst formation is a characteristic histologic manifestation of cutaneous infections with rapid-growing Mycobacterium species,” American Journal of Clinical Pathology, vol. 130, no. 4, pp. 514–517, 2008. View at: Publisher Site | Google Scholar
  25. J. Fowler and S. D. Mahlen, “Localized cutaneous infections in immunocompetent individuals due to rapidly growing mycobacteria,” Archives of Pathology and Laboratory Medicine, vol. 138, no. 8, pp. 1106–1109, 2014. View at: Publisher Site | Google Scholar
  26. L. Chandler, “Chapter 20. Challenges in clinical microbiology testing,” in Accurate Results in the Clinical Laboratory. A Guide to Error Detection and Correction, D. S. Young, Ed., pp. 315–326, Elsevier, Amsterdam, the Netherland, 2013. View at: Publisher Site | Google Scholar
  27. H. Marrakchi, M.-A. Lanéelle, and M. Daffé, “Mycolic acids: structures, biosynthesis, and beyond,” Cell Chemical Biology, vol. 21, no. 1, pp. 67–85, 2014. View at: Publisher Site | Google Scholar
  28. J. S. Schorey and L. Sweet, “The mycobacterial glycopeptidolipids: structure, function, and their role in pathogenesis,” Glycobiology, vol. 18, no. 11, pp. 832–841, 2008. View at: Publisher Site | Google Scholar
  29. M. Fujii, Y. Mizutani, T. Sakuma et al., “Corynebacterium kroppenstedtii in granulomatous mastitis: analysis of formalin-fixed, paraffin-embedded biopsy specimens by immunostaining using low-specificity bacterial antisera and real-time polymerase chain reaction,” Pathology International, vol. 68, no. 7, pp. 409–418, 2018. View at: Publisher Site | Google Scholar
  30. M. D. Collins, E. Falsen, E. Akervall, B. Sjoden, and A. Alvarez, “Note: Corynebacterium kroppenstedtii sp. nov., a novel corynebacterium that does not contain mycolic acids,” International Journal of Systematic Bacteriology, vol. 48, no. 4, pp. 1449–1454, 1998. View at: Publisher Site | Google Scholar
  31. J. A. Roberts and J. Lipman, “Pharmacokinetic issues for antibiotics in the critically ill patient,” Critical Care Medicine, vol. 37, no. 3, pp. 840–851, 2009, quiz 859. View at: Publisher Site | Google Scholar
  32. N. Franck, A. Cabie, B. Villette, B. Amor, M. Lessana-Leibowitch, and J. P. Escande, “Treatment of Mycobacterium chelonae-induced skin infection with clarithromycin,” Journal of the American Academy of Dermatology, vol. 28, no. 6, pp. 1019–1021, 1993. View at: Publisher Site | Google Scholar
  33. S. Terry, N. H. Timotby, J. J. Zurio, and E. K. Manders, “Mycobacterium chelonae: nonhealing leg ulcers treated successfully with an oral antibiotic,” Journal of the American Board of Family Practice, vol. 14, pp. 457–461, 2001. View at: Google Scholar
  34. N. Levine and J. G. Rothschild, “Treatment of Mycobacterium chelonae infection with controlled localized heating,” Journal of the American Academy of Dermatology, vol. 24, no. 5, pp. 867–870, 1991. View at: Publisher Site | Google Scholar
  35. Y. Eishi, Propionibacterium acnes as a cause of sarcoidosis, InTechOpen, London, UK, 2013. View at: Publisher Site

Copyright © 2021 Yutaka Tsutsumi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views200
Downloads278
Citations

Related articles